Liquidia Co. (NASDAQ:LQDA) Insider Sells $22,558.32 in Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 1,649 shares of the stock in a transaction that occurred on Friday, April 19th. The shares were sold at an average price of $13.68, for a total transaction of $22,558.32. Following the transaction, the insider now directly owns 211,672 shares of the company’s stock, valued at $2,895,672.96. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Liquidia Price Performance

LQDA opened at $12.55 on Thursday. The company has a fifty day moving average price of $14.60 and a 200-day moving average price of $11.18. The firm has a market capitalization of $954.18 million, a P/E ratio of -10.46 and a beta of 0.16. Liquidia Co. has a one year low of $5.71 and a one year high of $16.99.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). The firm had revenue of $4.53 million for the quarter, compared to analysts’ expectations of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. On average, analysts expect that Liquidia Co. will post -1.01 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Fortitude Family Office LLC bought a new stake in shares of Liquidia during the 4th quarter worth $26,000. Tower Research Capital LLC TRC lifted its holdings in shares of Liquidia by 610.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,997 shares of the company’s stock worth $108,000 after acquiring an additional 7,731 shares during the last quarter. Aigen Investment Management LP bought a new stake in shares of Liquidia during the 3rd quarter worth $80,000. SG Americas Securities LLC bought a new stake in shares of Liquidia during the 3rd quarter worth $84,000. Finally, Greenleaf Trust bought a new stake in shares of Liquidia during the 4th quarter worth $164,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LQDA has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of Liquidia in a research note on Wednesday, April 10th. HC Wainwright lifted their price objective on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, March 14th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $21.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).